Allergy Therapeutics (AGY.LSE)

Allergy Therapeutics share price today, ATLAS forecast and fair value

Healthcare · Drug Manufacturers - Specialty & Generic · London Stock Exchange · United Kingdom

£0.043▲ 0.00%

Prices as of Oct 27, 2026 · GBP

ATLAS fair value

ATLAS has no fair value for this stock today.

Chance of rising in 1 month

48%

that it ends higher than today in 21 sessions

0%coin flip 50%100%

This is just the summary. See everything on Allergy Therapeutics in ATLAS

ATLAS's own quantitative analysis, all in one place.

Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
Officers and shareholdersWho runs the company and which funds hold its shares.
Customer and supplier mapWho it does business with, from its own filings.
ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
AlertsWe let you know when something changes in your stocks.

See everything included

Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
NewsThe latest on the company, in one place.
Crisis simulatorHow your portfolio would do in a crash like 2008.
Practice risk-free$10,000 in virtual money to invest at real prices.
Global screenerSearch US stocks and stocks from 47 countries with filters.

On Allergy Therapeutics

Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
Officers and shareholdersWho runs the company and which funds hold its shares.
Customer and supplier mapWho it does business with, from its own filings.
Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
NewsThe latest on the company, in one place.

And for you

ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
AlertsWe let you know when something changes in your stocks.
Crisis simulatorHow your portfolio would do in a crash like 2008.
Practice risk-free$10,000 in virtual money to invest at real prices.
Global screenerSearch US stocks and stocks from 47 countries with filters.

Get started →

Plans from €3.99 a month.

ATLAS's model gives Allergy Therapeutics a 48% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.

In half of the simulated outcomes the price ends between £0.038 and £0.046; in 9 out of 10, between £0.032 and £0.055. Estimated annual volatility is 51%.

Price, last 12 months (weekly close)

Key numbers

Market cap: £287M
Market cap (USD): $382M
52-week high: £0.121
52-week low: £0.041
Revenue (12 months): £57.3M
Gross margin: 52.2%
Operating margin: -31.4%
Net margin: -84.1%
Beta: 0.92

What this means

ATLAS does not publish a fair value for AGY.LSE right now, but it does show its odds of rising: close to a coin flip.

Over the last 52 weeks AGY.LSE has traded between £0.041 and £0.121. Today it is 64.9% below that high and 5% above its low.

Its beta is 0.92: it moves roughly in line with the market.

About the company

Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally.

Want to see everything about Allergy Therapeutics?

Get started →

Plans from €3.99 a month.

Comparable companies

Other companies in the same line of business:

Frequently asked questions

What does Allergy Therapeutics do?

What is the chance AGY.LSE goes up next month?

48%: close to a coin flip. In half of the simulated outcomes, AGY.LSE ends the month between £0.038 and £0.046.

How big is Allergy Therapeutics and what is its P/E ratio?

Allergy Therapeutics's market capitalization is £287M. We do not show a P/E because it has no positive earnings to base one on.

How volatile is AGY.LSE?

ATLAS estimates annual volatility at 51%. In a typical month, half of the outcomes end between £0.038 and £0.046.

Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer